Decibel Therapeutics, Inc. Operating Income
Decibel Therapeutics, Inc. reported Operating Income of -$19.04 million for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-11.
Discontinued › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2023-08-11
- Decibel Therapeutics, Inc. operating income (loss) for the quarter ending 2023-06-30 was -$19.04M.
- Decibel Therapeutics, Inc. operating income (loss) for the quarter ending 2023-03-31 was -$14.12M.
- Decibel Therapeutics, Inc. operating income (loss) for the quarter ending 2022-12-31 was -$16.49M.
- Decibel Therapeutics, Inc. operating income (loss) for the quarter ending 2022-09-30 was -$16.35M.
- Decibel Therapeutics, Inc. operating income (loss) for fiscal 2022 was -$63.96M.
- Decibel Therapeutics, Inc. operating income (loss) for fiscal 2021 was -$50.23M.
- Decibel Therapeutics, Inc. operating income (loss) for fiscal 2020 was -$39.56M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2023-06-30 | -$19.04M 10-Q · filed 2023-08-11 | -$33.16M 10-Q · filed 2023-08-11 | -$49.65M derived: sum of 3 quarters · filed 2023-08-11 | -$66.00M derived: sum of 4 quarters · filed 2023-08-11 |
| 2023-03-31 | -$14.12M 10-Q · filed 2023-05-15 | -$30.61M derived: sum of 2 quarters · filed 2023-05-15 | -$46.96M derived: sum of 3 quarters · filed 2023-05-15 | -$64.06M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-12-31 | -$16.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$32.84M derived: sum of 2 quarters · filed 2023-03-14 | -$49.94M derived: sum of 3 quarters · filed 2023-08-11 | -$63.96M 10-K · filed 2023-03-14 |
| 2022-09-30 | -$16.35M 10-Q · filed 2022-11-09 | -$33.45M derived: sum of 2 quarters · filed 2023-08-11 | -$47.47M 10-Q · filed 2022-11-09 | -$60.37M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-06-30 | -$17.10M 10-Q · filed 2023-08-11 | -$31.12M 10-Q · filed 2023-08-11 | -$44.02M derived: sum of 3 quarters · filed 2023-08-11 | -$58.72M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$14.02M 10-Q · filed 2023-05-15 | -$26.92M derived: sum of 2 quarters · filed 2023-05-15 | -$41.62M derived: sum of 3 quarters · filed 2023-05-15 | -$53.35M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$12.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$27.60M derived: sum of 2 quarters · filed 2023-03-14 | -$39.33M derived: sum of 3 quarters · filed 2023-03-14 | -$50.23M 10-K · filed 2023-03-14 |
| 2021-09-30 | -$14.70M 10-Q · filed 2022-11-09 | -$26.43M derived: sum of 2 quarters · filed 2022-11-09 | -$37.33M 10-Q · filed 2022-11-09 | -$50.34M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$11.73M 10-Q · filed 2022-08-10 | -$22.63M 10-Q · filed 2022-08-10 | -$35.64M derived: sum of 3 quarters · filed 2022-08-10 | -$42.72M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$10.90M 10-Q · filed 2022-05-12 | -$23.91M derived: sum of 2 quarters · filed 2022-05-12 | -$31.00M derived: sum of 3 quarters · filed 2022-05-12 | -$38.85M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$13.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$20.09M derived: sum of 2 quarters · filed 2022-03-18 | -$27.95M derived: sum of 3 quarters · filed 2022-03-18 | -$39.56M 10-K · filed 2022-03-18 |
| 2020-09-30 | -$7.09M 10-Q · filed 2021-11-10 | -$14.94M derived: sum of 2 quarters · filed 2021-11-10 | -$26.56M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$7.85M 10-Q · filed 2021-08-10 | -$19.47M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | -$11.61M 10-Q · filed 2021-05-13 |